Episode 201: Ashley Kalinauskas - How Torigen is Innovating Veterinary Oncology With Immunotherapy

My guest today is Ashley Kalinauskas, CEO of Torigen Pharmaceuticals. What we discuss with Ashley: How her graduate research at Notre Dame led to the founding of Torigen Pharmaceuticals. Their approach provides an alternative to chemotherapy by using immunotherapy. The company aims to make cancer treatment more accessible and affordable for pet owners. Promising results have been seen in aggressive cancers like hemangiosarcoma. How Torigen is utilizing digital pathology with the Concentriq platform to improve cancer diagnostics. Torigen is conducting research into additional applications, including equine and exotic animal cancers. Studying spontaneous cancer in pets provides valuable insights for human oncology research. Veterinary immunotherapy advancements have the potential to influence human cancer treatments. Immunotherapy is playing an increasingly important role in both veterinary and human medicine.   Links for this episode: Pathologists' Assistant Shadowing Network Health Podcast Network  LabVine Learning Dress A Med scrubs Digital Pathology Club   Torigen Pharmaceuticals Evaluation of an autologous cancer vaccine for the treatment of metastatic canine hemangiosarcoma: a preliminary study New Hope For Pets In The Fight Against Cancer: Fast, Accurate Diagnoses From Torigen Pharmaceuticals And Proscia   People of Pathology Podcast: Twitter Instagram